Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Market Outlook: PharmAsia News Earnings Call Roundup

This article was originally published in PharmAsia News

Executive Summary

In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets

You may also be interested in...



GlaxoSmithKline Steers Away From 'White Pills in Western Markets'

"This organization is changing, and the change has only just begun," declared GlaxoSmithKline's chief executive Andrew Witty in an interview on July 22 after the company reported second-quarter results

GSK/Dr. Reddy’s Deal To Co-Promote Branded Generics In Emerging Markets

GlaxoSmithKline and India-based generics giant Dr. Reddy's now must iron out how best to sell branded generics in diverse emerging markets after reaching a strategic alliance, announced June 15 (PharmAsia News, June 15, 2009)

New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus, Which Has Been Trapped In Troubled Financial Seas

BEIJING - A new vaccine joint venture with the United Kingdom's GlaxoSmithKline could become a lifesaver for the Chinese biologics outfit Shenzhen Neptunus Interlong Bio-Technique Co., which has been fighting to stay afloat amid a maelstrom of earnings losses, staff layoffs and a partial halt in production

Related Content

UsernamePublicRestriction

Register

SC072301

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel